{"id":195247,"date":"2024-08-26T12:53:36","date_gmt":"2024-08-26T17:53:36","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/08\/patch-wearable-cardioverter-defibrillator-safe-and-effective"},"modified":"2024-08-26T12:53:36","modified_gmt":"2024-08-26T17:53:36","slug":"patch-wearable-cardioverter-defibrillator-safe-and-effective","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/08\/patch-wearable-cardioverter-defibrillator-safe-and-effective","title":{"rendered":"Patch-Wearable Cardioverter-Defibrillator Safe and Effective"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/patch-wearable-cardioverter-defibrillator-safe-and-effective2.jpg\"><\/a><\/p>\n<p>A novel, water-resistant patch-wearable cardioverter-defibrillator (P-WCD) is safe and effective for patients at risk for sudden cardiac arrest, according to a study published in the Aug. 6 issue of the Journal of the American College of Cardiology.<\/p>\n<p>John Hummel, M.D., from The Ohio State University in Columbus, and colleagues assessed the safety and clinical effectiveness of a novel P-WCD. The analysis included 290 patients at risk for sudden cardiac arrest due to ventricular tachycardia\/ventricular fibrillation who were not candidates for or refused an implantable defibrillator.<\/p>\n<p>The researchers found that the clinically significant cutaneous adverse device effect rate was 2.30 percent, with no severe adverse effects. There were no device-related deaths or serious adverse events reported. The inappropriate shock rate was 0.36 per 100 patient-months. Nine patients received 11 shocks, of which nine shocks were adjudicated to be appropriate. Eight of nine appropriate shocks were successful with a single shock. Median wear time compliance was 23.5 hours per day.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A novel, water-resistant patch-wearable cardioverter-defibrillator (P-WCD) is safe and effective for patients at risk for sudden cardiac arrest, according to a study published in the Aug. 6 issue of the Journal of the American College of Cardiology. John Hummel, M.D., from The Ohio State University in Columbus, and colleagues assessed the safety and clinical effectiveness [\u2026]<\/p>\n","protected":false},"author":707,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,1977],"tags":[],"class_list":["post-195247","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-wearables"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/195247","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/707"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=195247"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/195247\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=195247"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=195247"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=195247"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}